Abstract
Misleading terminology and arbitrary divisions stymie drug trials and can give false hope about the potential of tailoring drugs to individuals, warns Stephen Senn. [Figure not available: see fulltext.].
| Original language | English |
|---|---|
| Pages (from-to) | 619-621 |
| Number of pages | 3 |
| Journal | Nature |
| Volume | 563 |
| Issue number | 7733 |
| DOIs |
|
| Publication status | Published - 29 Nov 2018 |
Keywords
- Medical research
- Personalized medicine